



Attorney Docket No.: MSK.P-075

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Turk et al.
Serial No.: 10/680,062
Filed: October 6, 2003
Confirmation: 7430
Title: Liposomal system and method of using same

SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application.

Copies of the references are provided herewith.

No fee is believed to be due with this paper as we have not received an action on the merits. The Commissioner is authorized to charge any fees which may be due to Deposit Account Number 15-0610.

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina T. Larson

Marina T. Larson, PhD , Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
Phone: 970-468-6600
Fax: 970-468-0104

CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on March 8, 2004

3-8-2004
Date of Signature

Lori South

Lori South



PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/680,062
				Filing Date	10/6/2003
				First Named Inventor	Turk et al.
				Art Unit	1615
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	MSK.P-075

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

<i>Application Number</i>	10/680,062
<i>Filing Date</i>	10/6/2003
<i>First Named Inventor</i>	Turk et al.
<i>Art Unit</i>	1615
<i>Examiner Name</i>	

T²

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ALEXANDER ET AL., Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope, Am. J. Obstet. Gynecol., 1996, Page(s) 1586-1593, Volume 175
	BOEL ET AL., BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes, Immunity, 1995, Page(s) 167-175, Volume 2
	BOON ET AL., Human Tumor Antigens Recognized by T Lymphocytes, J. Exp. Med., 1996, Page(s) 725-729, Volume 183
	BRICHARD ET AL., A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes, Eur. J. Immunol., 1996, Page(s) 224-230, Volume 26
	CASTELLI ET AL., Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8+ Cytotoxic T Lymphocytes, J. Exp. Med., 1995, Page(s) 363-368, Volume 181
	CHANG ET AL., Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes, Vaccine, 1999, Page(s) 1540-1548, Volume 17
	CHANG ET AL., Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes, Vaccine, 2001, Page(s) 3608-3614, Volume 19
	COULIE ET AL., A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA, 1995, Page(s) 7976-7980, Volume 92
	DISIS ET AL., Oncogenic proteins as tumor antigens, Curr. Opin. Immunol., 1996, Page(s) 637-642, Volume 8
	FINN ET AL., MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines, Immunological Reviews, 1995, Page(s) 61-89, No. 145
	FISK ET AL., Identification of an Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines , J. Exp. Med., 1995, Page(s) 2109-2117, Volume 181

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/680,062
				<i>Filing Date</i>	10/6/2003
				<i>First Named Inventor</i>	Turk et al.
				<i>Art Unit</i>	1615
				<i>Examiner Name</i>	
Sheet	3	of	4	Attorney Docket Number	MSK.P-075


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		GAUGLER ET AL., Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes, J. Exp. Med., 1994, Page(s) 921-930, Volume 179			
		GUILLOUX ET AL., A Peptide Recognized by Human Cytolytic T Lymphocytes on HLA-A2 Melanomas Is Encoded by an Intron Sequence of the N-Acetylglucosaminyltransferase V Gene, J. Exp. Med., 1996, Page(s) 1173-1183, Volume 183			
		KAWAKAMI ET AL., Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression, J. Immunol., 1995, Page(s) 3961-3968, Volume 154			
		KAWAKAMI ET AL., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection, Proc. Natl. Acad. Sci. USA, 1994, Page(s) 6458-6462, Volume 91			
		PEOPLES ET AL., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER1/neu-derived peptide, Proc. Natl. Acad. Sci. USA, 1995, Page(s) 432-436, Volume 92			
		PINILLA-IBARZ ET AL., Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses, Blood, 03/01/2000, Page(s) 1781-1787, Volume 95, No. 5			
		RESSING ET AL., Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-positive Cervical Lesions against a Human Leukocyte Antigen-A *0201-restricted E7-encoded Epitope, Cancer Research, 1996, Page(s) 582-588, Volume 56			
		RICHARDS ET AL., Liposomes Containing Lipid A Serve as an Adjuvant for Induction of Antibody and Cytotoxic T-Cell Responses against RTS,S Malaria Antigen, Infection and Immunity, 1998, Page(s) 2859-2865, Volume 66, No. 6			
		ROBBINS ET AL., Cloning of a New Gene Encoding an Antigen Recognized by Melanoma-Specific HLA-A24-Restricted Tumor-Infiltrating Lymphocytes, J. Immunol., 1995, Page(s) 5944-5950, Volume 154			
		ROBBINS ET AL., A Mutated β-Catenin Gene Encodes a melanoma-specific Antigen Recognized by Tumor Infiltrating Lymphocytes, J. Exp. Med., 1996, Page(s) 1185-1192, Volume 183			
		ROBBINS ET AL., Human tumor antigens recognized by T cells, Curr. Opin. Immunol., 1996, Page(s) 628-636, Volume 8			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/05b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/680,062
Sheet	4	of	4	Filing Date	10/6/2003
				First Named Inventor	Turk et al.
				Art Unit	1615
				Examiner Name	
				Attorney Docket Number	MSK.P-075

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		SAMUEL ET AL., Immunogenicity and Antitumor Activity of a Liposomal MUC1 Peptide-Based Vaccine, Int. J. Cancer, 1998, Page(s) 295-302, Volume 75			
		TOPALIAN ET AL., Melanoma-specific CD4 ⁺ T Cells Recognize Nonmutated HLA-DR-restricted Tyrosinase Epitopes, J. Exp. Med., 1996, Page(s) 1965-1971, Volume 183			
		TRAVERSARI ET AL., A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E, J. Exp. Med., 1992, Page(s) 1453-1457, Volume 176			
		VAN DEN EYNDE ET AL., A New Family of Genes Coding for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on a Human Melanoma, J. Exp. Med., 1995, Page(s) 689-698, Volume 182			
		VAN DER BRUGGEN ET AL., A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma, Science, 1991, Page(s) 1643-1647, Volume 254			
		VARSHAVSKY, The N-end rule: Functions, mysteries, uses, Proc. Natl. Acad. Sci. USA, 1996, Page(s) 12142-12149, Volume 93			
		WOLFEL ET AL., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes, Eur. J. Immunol., 1994, Page(s) 759-764, Volume 24			
		WOLFEL ET AL., A p16 ^{INK4a} -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma, Science, 1995, Page(s) 1281-1284, Volume 269			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.